Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt’s Macular Dystrophy (SMD)

Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt’s
Macular Dystrophy (SMD).

Type: Interventional

Status of the trial: Completed

Orphan Drug Recognition: NA

Inclusion

Opening Date: 2011-11-01
Closing Date: 2015-09-01

Criteria

More information

Children: No

Adults: Yes

Funder Type: industry

HCP: Principal investigators

Moorfields Eye Hospital NHS Foundation Trust

HCP: Other investigators

Within ERN-EYE members

Principal investigators

Other investigators

Workgroups

Retinal Rare Eye Diseases (WG1)

Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt’s Macular Dystrophy (SMD)

Within ERN-EYE members

Subscribe

This ERN is supported by: